FluoGuide A/S (STO:FLUO)

Market Cap	560.78M
Revenue (ttm)	-703.14K
Net Income (ttm)	-51.97M
Shares Out	16.35M
EPS (ttm)	-3.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,836
Average Volume	11,232
Open	35.30
Previous Close	35.30
Day's Range	34.00 - 35.70
52-Week Range	29.10 - 57.00
Beta	0.76
RSI	37.53
Earnings Date	Feb 25, 2026

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. FluoGuide A/S was incorporated in ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUO

Financial Performance

In 2024, FluoGuide's revenue was 385,000, a decrease of -8.98% compared to the previous year's 423,000. Losses were -28.96 million, -24.54% less than in 2023.

Financial numbers in DKK